Status epilepticus in a case of Wilson’s disease during D-pencillamine treatment

Ülkü Türk-Börü, Abdulkadir Koçer, Recep Alp, Mahmut Giınmiş, Mustafa Giınmiş

a Neurology Department; b Internal Medicine Department; c Ophthalmology Department; Dr Lütfi Kirdar Kortal Education and Research Hospital, Kartal-Istanbul, Turkey

We report on a case of Wilson’s disease in a young male presenting with status epilepticus during D-pencillamine treatment. The patient was admitted to our neurological clinic for status epilepticus and was successfully treated with antiepileptic drugs. He had been on regular D-pencillamine treatment for three years. Magnetic resonance imaging showed lesions bilaterally in subcortical areas of frontal lobes, putamen, thalamus, globus pallidus, and caudate nuclei. Wilson’s disease had been diagnosed. Few patients with Wilson’s disease presenting with epilepsy and status epilepticus have been reported. Although the patient had received D-pencillamine treatment, the diagnosis of Wilson’s disease should be considered in patients who present with status epilepticus.

Introduction

Wilson’s disease (WD), or hepatolenticular degeneration, is a neurodegenerative disease of copper metabolism. WD is a treatable autosomal recessive disease localised to chromosome 13, leading to an excessive accumulation of copper in the liver, cornea, kidneys and the basal ganglia of the brain [1]. Other brain structures, such as the thalamus, the cerebellum and the cerebral white matter, may also be affected. Dysarthria, dystonia, cerebellar signs, rigidity, gait and postural abnormalities, tremor, chorea, and dementia are neurological findings seen in WD [2]. Seizures are a relatively rare feature of WD [3–5].

Case report

A 19-year-old male was admitted to our neurological outpatient clinic for status epilepticus with right-sided focal onset. The focal motor onset – right-sided and firstly clonic in nature, then becoming generalised tonic-clonic seizures – continued for two days. Each seizure complex with frontal automatisms continued for 10–15 minutes and was repeated sixteen times over two days; status epilepticus was diagnosed. The patient was unconscious due to generalised convulsive status epilepticus of the intermitent type and was treated with intravenous diazepam and phenytoin. From the third day the patient’s level of consciousness improved and he responded to verbal stimulation. He also exhibited explosive dysarthric speech, rigidity, dystonia and bilateral pyramidal signs. Tandem walking was ataxic. Cognitive examination showed emotional lability and a minimal examination score of 18/30. Slit-lamp examination disclosed Kayser-Fleischer rings. He had been diagnosed with WD five years previously and had received 400 mg/day D-pencillamine regularly for 3 years. Routine biochemical tests, including liver function tests, were normal. He had low plasma copper (24 mg/ml [100 mg/ml]) and caeruloplasmin (10 mg/100 ml [N: ≥20 mg/dl]) concentrations. The 24-hour excreted copper concentration was very high (256 mg/dl [40–80 mg/dl]). Cerebrospinal fluid findings were normal. No provocation factor was involved. The patient was followed in intensive care and due to a technical problem with the EEG equipment an EEG was taken 2 days after the status epilepticus had ended and showed slow background activity, bifrontal slow theta waves and spikes (fig. 1). Ultrasound of the liver was normal. Cranial MRI showed that bilateral subcortical area of frontal lobe, putamen, thalamus, globus pallidus, and caudate nucleus involved lesions that were hypointense on T1 weighted and hyperintense on T2 images. Additionally lesions on pons, mesenzefalon, and periaquaductal gray matter, which were hypointense on T1 weighted images and hyperintense on T2 weighted images, were seen (fig. 2a, b). Following acute hospitalisation he received 1400 mg/day carbamazepine and 400 mg/day D-pencillamine, and has remained seizure-free for two years.

Discussion

The symptoms of WD may be variable, with neurological and psychiatric findings associated with liver disease predominating. Epileptic seizures are rarely seen in WD. Epileptic seizures in various forms, e.g. generalised tonic-clonic, absence, focal motor and psychomotor, occur as an early or late manifestation of WD [5, 6]. Several mechanisms have been suggested for increased seizure activity. As shown in animal studies, copper deposition in the brain may cause ictus by inhibition of membrane ATPase [7], and thus focal and generalised seizures may be related to copper deposition in the brain. Copper deposition occurs in the lentiform nuclei, thalamus, brainstem nuclei, cerebral cortex, and cerebral and cerebellar white matter. Neuronal loss, gliosis, laminar necrosis, spongy degeneration and cavitation may also be responsible for focal seizure activity [8]. D-pencillamine induces pyridoxine deficiency, which may be a predisposing factor for seizures [6, 9]. Patients with neurological symptoms and signs of Wilson’s disease, and even presymptomatic patients, may experience worsening of their condition after starting therapy with D-pencillamine [10]. Dystonia and bradykinesia correlated with the striatum and especially putamen lesions, and dysarthria correlated with both putamen and caudate lesions. Penicillamine treatment in Wilson’s disease may cause dystonia with thalamic and brainstem lesions [10, 11]. We conjectured that in the present case the severe seizure problem, and especially dystonia, could be related to D-pencillamine therapy.

Our patient had status epilepticus with
focal and secondary generalised tonic-clonic seizures for 48 hours. The EEG recording taken after two days indicated focal epileptiform activity in the frontal regions. In the English-language literature we were unable to find any report of status epilepticus in WD under D-penicillamine treatment. A case report in Japanese was found via MEDLINE [12]. Cerebral MR findings correlate well with neurological findings in WD. The majority of patients without neurological symptoms have normal MR scans, while those with neurological symptoms have abnormal scans [13, 14]. The MRI study in our case showed bilateral subcortical white matter lesions of the frontal lobe, and other classic lesions in which copper may be deposited. We postulate that the frontal lesions may have an aetiological relationship with the seizures in our patient. Because of the existence of frontal automatism and the EEG focus on the frontal regions, the patient’s seizures were thought to originate from the frontal lobe. As far as we know this is the second reported case of WD associated with status epilepticus under D-penicillamine treatment. The diagnosis of Wilson’s disease should be considered in patients presenting with seizures and status epilepticus.

Correspondence: Ülkü Türk-Börü MD Neurology Department Dr Lütfi Kırdar Kartal Education and Research Hospital Kartal-Istanbul Turkey E-mail: uturkboru@hotmail.com

References
The many reasons why you should choose SMW to publish your research

What Swiss Medical Weekly has to offer:

- SMW’s impact factor has been steadily rising, to the current 1.537
- Open access to the publication via the Internet, therefore wide audience and impact
- Rapid listing in Medline
- LinkOut-button from PubMed with link to the full text website http://www.smw.ch (direct link from each SMW record in PubMed)
- No-nonsense submission – you submit a single copy of your manuscript by e-mail attachment
- Peer review based on a broad spectrum of international academic referees
- Assistance of our professional statistician for every article with statistical analyses
- Fast peer review, by e-mail exchange with the referees
- Prompt decisions based on weekly conferences of the Editorial Board
- Prompt notification on the status of your manuscript by e-mail
- Professional English copy editing
- No page charges and attractive colour offprints at no extra cost

Editorial Board
Prof. Jean-Michel Dayer, Geneva
Prof. Peter Gehr, Berne
Prof. André P. Perruchoud, Basel
Prof. Andreas Schaffner, Zurich
  (Editor in chief)
Prof. Werner Straub, Berne
Prof. Ludwig von Segesser, Lausanne

International Advisory Committee
Prof. K. E. Juhani Airaksinen, Turku, Finland
Prof. Anthony Bayes de Luna, Barcelona, Spain
Prof. Hubert E. Blum, Freiburg, Germany
Prof. Walter E. Haefeli, Heidelberg, Germany
Prof. Nino Kuenzli, Los Angeles, USA
Prof. René Lutter, Amsterdam, The Netherlands
Prof. Claude Martin, Marseille, France
Prof. Josef Patsch, Innsbruck, Austria
Prof. Luigi Tavazzi, Pavia, Italy

We evaluate manuscripts of broad clinical interest from all specialities, including experimental medicine and clinical investigation.

We look forward to receiving your paper!

Guidelines for authors:
http://www.smw.ch/set_authors.html

Impact factor Swiss Medical Weekly

<table>
<thead>
<tr>
<th>Year</th>
<th>0.770</th>
<th>1.162</th>
<th>1.537</th>
</tr>
</thead>
<tbody>
<tr>
<td>1995</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1996</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1997</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1998</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1999</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2000</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2001</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2002</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2003</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2004</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

EMH Swiss Medical Publishers Ltd.
SMW Editorial Secretariat
Farnburgerstrasse 8
CH-4132 Muttenz

Manuscripts: submission@smw.ch
Letters to the editor: letters@smw.ch
Editorial Board: red@smw.ch
Internet: http://www.smw.ch